Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – ...
Source: marketscreener.com